“Recently, clinical trials utilizing medical imaging technologies have surged, making Blinded Independent Central Review (BICR) increasingly important in trials. Imaging CROs like TI Image can help pharmaceutical companies and CROs reduce the time and cost required for regulatory approval, while providing high‑quality imaging data.” said Yoon Byung‑in, CEO of TI Image, expressing his intent to expand their imaging CRO business. TI Image operates as a subsidiary of CN&Research (ticker: 359090), a leading domestic CRO. Headquartered in Singapore, TI Image specializes in analyzing imaging data during clinical processes, with a focus on quality control, standardization, and independent assessment to enhance trial reliability. 이데일리
Yoon—who initially proposed founding GCCL, a joint venture between GC Green Cross and CN&Research—has helped grow the company's sales to approximately ₩16 billion in just three years after its establishment. He later transitioned to lead TI Image, with the aspiration of modeling the company after Clario, a premier US imaging CRO. The global imaging CRO market was valued at around ₩72.513 trillion (USD 5.02 billion) last year, with Clario’s revenue at approximately ₩13 trillion.
Market Size & Domestic Prospects
For pharma companies, primary and secondary endpoint outcomes (e.g., progression‑free survival, overall survival, pathological complete response) are crucial determinants of a clinical trial's success. As imaging technologies have advanced, and specialized CROs have emerged, BICR is increasingly being included as an endpoint in trials. In solid tumor trials, for example, CT or MRI scans are used to measure tumor size changes to assess whether cancer has shrunk, remained stable, or grown. The US FDA also recommends the incorporation of imaging analysis in trials.
TI Image leverages 30 years of CRO experience and extensive imaging data. Their proprietary ImageTrial system—a CTIMS with FDA 510(k) clearance and CDISC compliance—optimizes independent image review.
Yoon notes that although the Korean imaging CRO market is in its infancy, it holds high growth potential. He points out that while global CROs already maintain in‑house centralized imaging teams—or in Clario’s case, a standalone imaging CRO—breaking even solely on Korea‑based operations may not be feasible. That’s why TI Image bases its headquarters in Singapore, to target global markets.
He also highlights the evolving FDA guidelines that now extend independent imaging reviews beyond oncology to non‑oncology fields, providing new business opportunities. 이데일리
TI Image has established a strategic partnership with AIM (Asan Image Metrics), a lab within Asan Medical Center—recognizing AIM as Korea’s first Central Imaging Core Lab. Together, they support imaging‑based clinical trials. Yoon emphasizes that TI Image offers not just image reading services, but also customized imaging solutions that boost result reliability and optimize decision‑making.
AI Integration & Future Revenue Outlook
Yoon is confident TI Image will significantly increase its revenue this year, aiming to double last year's results. Since entering the Korean market, the company has undertaken more than 40 clinical trials, collaborating with Asan Medical Center and contributing to several approvals from the Ministry of Food and Drug Safety.
He stated: “Until now, demand was largely overseas. We will focus on reversing that trend, enabling domestic pharma and biotech firms to conduct trials more efficiently, with both temporal and geographic advantages.”
This year, AI‑based software development is a corporate priority. By integrating AI algorithms to assist independent raters, TI Image aims to speed up analysis, improve accuracy, and quantify MRI/CT data to strengthen treatment efficacy evaluations. Yoon underscored that TI Image is not merely a service provider; rather, they deliver global‑level clinical expertise, IT‑based data management, and academic support to maximize research value.
“Recently, clinical trials utilizing medical imaging technologies have surged, making Blinded Independent Central Review (BICR) increasingly important in trials. Imaging CROs like TI Image can help pharmaceutical companies and CROs reduce the time and cost required for regulatory approval, while providing high‑quality imaging data.” said Yoon Byung‑in, CEO of TI Image, expressing his intent to expand their imaging CRO business. TI Image operates as a subsidiary of CN&Research (ticker: 359090), a leading domestic CRO. Headquartered in Singapore, TI Image specializes in analyzing imaging data during clinical processes, with a focus on quality control, standardization, and independent assessment to enhance trial reliability. 이데일리
Yoon—who initially proposed founding GCCL, a joint venture between GC Green Cross and CN&Research—has helped grow the company's sales to approximately ₩16 billion in just three years after its establishment. He later transitioned to lead TI Image, with the aspiration of modeling the company after Clario, a premier US imaging CRO. The global imaging CRO market was valued at around ₩72.513 trillion (USD 5.02 billion) last year, with Clario’s revenue at approximately ₩13 trillion.
Market Size & Domestic Prospects
For pharma companies, primary and secondary endpoint outcomes (e.g., progression‑free survival, overall survival, pathological complete response) are crucial determinants of a clinical trial's success. As imaging technologies have advanced, and specialized CROs have emerged, BICR is increasingly being included as an endpoint in trials. In solid tumor trials, for example, CT or MRI scans are used to measure tumor size changes to assess whether cancer has shrunk, remained stable, or grown. The US FDA also recommends the incorporation of imaging analysis in trials.
TI Image leverages 30 years of CRO experience and extensive imaging data. Their proprietary ImageTrial system—a CTIMS with FDA 510(k) clearance and CDISC compliance—optimizes independent image review.
Yoon notes that although the Korean imaging CRO market is in its infancy, it holds high growth potential. He points out that while global CROs already maintain in‑house centralized imaging teams—or in Clario’s case, a standalone imaging CRO—breaking even solely on Korea‑based operations may not be feasible. That’s why TI Image bases its headquarters in Singapore, to target global markets.
He also highlights the evolving FDA guidelines that now extend independent imaging reviews beyond oncology to non‑oncology fields, providing new business opportunities. 이데일리
TI Image has established a strategic partnership with AIM (Asan Image Metrics), a lab within Asan Medical Center—recognizing AIM as Korea’s first Central Imaging Core Lab. Together, they support imaging‑based clinical trials. Yoon emphasizes that TI Image offers not just image reading services, but also customized imaging solutions that boost result reliability and optimize decision‑making.
AI Integration & Future Revenue Outlook
Yoon is confident TI Image will significantly increase its revenue this year, aiming to double last year's results. Since entering the Korean market, the company has undertaken more than 40 clinical trials, collaborating with Asan Medical Center and contributing to several approvals from the Ministry of Food and Drug Safety.
He stated: “Until now, demand was largely overseas. We will focus on reversing that trend, enabling domestic pharma and biotech firms to conduct trials more efficiently, with both temporal and geographic advantages.”
This year, AI‑based software development is a corporate priority. By integrating AI algorithms to assist independent raters, TI Image aims to speed up analysis, improve accuracy, and quantify MRI/CT data to strengthen treatment efficacy evaluations. Yoon underscored that TI Image is not merely a service provider; rather, they deliver global‑level clinical expertise, IT‑based data management, and academic support to maximize research value.